Crossmark

New insights into JAK2 germline variant-driven stromal cell alterations and proinflammatory bone marrow niche remodeling in myeloproliferative neoplasms

Crossref DOI link: https://doi.org/10.1038/s41375-026-02937-y

Published Online: 2026-04-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nishimura, Komei https://orcid.org/0009-0001-3788-8897
Ono, Ryoichi https://orcid.org/0000-0002-1774-7843
Nagaharu, Keiki https://orcid.org/0000-0002-6139-4256
Ohya, Eiko

Tsuji, Takuya https://orcid.org/0009-0002-5455-401X
Ikejiri, Makoto

Nakamura, Akihide https://orcid.org/0009-0001-7944-7213
Nosaka, Tetsuya https://orcid.org/0000-0002-0037-7049
Tawara, Isao https://orcid.org/0000-0002-5426-9422
Sugimoto, Yuka https://orcid.org/0000-0002-3263-3270
Ohishi, Kohshi https://orcid.org/0000-0001-8136-9907
License Information

Text and Data Mining valid from 2026-04-01

Version of Record valid from 2026-04-01
More Information

Article History

Received: 4 October 2025

Revised: 20 February 2026

Accepted: 12 March 2026

First Online: 1 April 2026

Competing interests

: YS reports honoraria from PharmaEssentia Japan KK, Novartis Pharmaceutical, GSK, and research funds under contract from Incyte Biosciences Japan, Toyo Kohan KK, MSD, Sumitomo Pharma Co., Ltd, Sobi Japan. K Nagaharu reports research funds under Takeda Pharmaceutical internationals. KO reports research funds under contract from PharmaEssentia Japan KK, Abbvie Inc. The other authors declare no competing interests.

Document is current

Any future updates will be listed below